Market Place
Sourcing Support
Biogen Boosts Sales Forecast as `New Biogen` Emerges
31 Jul 2025 //
FIERCE PHARMA
Biogen’s Leqembi Advances as CEO Eyes Pipeline Rebuild
31 Jul 2025 //
BIOSPACE
Biogen, Eisai’s Leqembi Slows Alzheimer’s Over 4-Year Treatment
31 Jul 2025 //
BIOSPACE
Four-Year LEQEMBI® Data Shows Benefit in Early Alzheimer’s
30 Jul 2025 //
PR NEWSWIRE
ZURZUVAE Gets CHMP Nod for Postpartum Depression
25 Jul 2025 //
GLOBENEWSWIRE
With $2 B Investment, Biogen Will Increase Its Presence in NC
22 Jul 2025 //
FIERCE PHARMA
Biogen to Present Alzheimer’s Research at Conference
21 Jul 2025 //
GLOBENEWSWIRE
Lecanemab Drug Discovery Wins 9th Bioindustry Award in Japan
16 Jul 2025 //
PR NEWSWIRE
Biogen, Stoke Reveal Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
GLOBENEWSWIRE
Stoke, Biogen Unveil Zorevunersen Data for Dravet Syndrome
10 Jul 2025 //
BUSINESSWIRE
Sage`s Search for Lifeline Ran Into Defiant Biogen CEO
03 Jul 2025 //
BIOSPACE
Biogen Starts Phase 3 Study of Felzartamab for Nephropathy
30 Jun 2025 //
GLOBENEWSWIRE
Nusinersen Data Highlights Biogen`s Commitment to SMA Research
27 Jun 2025 //
GLOBENEWSWIRE
Biogen to Take Spinraza Follow-Up Into Registrational Studies
25 Jun 2025 //
FIERCE BIOTECH
Ionis, Biogen Advance Salanersen Into SMA Registrational Trials
25 Jun 2025 //
BUSINESSWIRE
Biogen Advances Spinal Muscular Atrophy Asset to Phase 1 Studies
25 Jun 2025 //
GLOBENEWSWIRE
Biogen Starts Ph3 Omaveloxolone in Pediatric Friedreich Ataxia
18 Jun 2025 //
GLOBENEWSWIRE
Biogen, BMS and Novartis bag spots on Cannes Lions shortlists
16 Jun 2025 //
FIERCE PHARMA
Dapirolizumab Ph3 SLE Data Shows Less Fatigue & Disease Activity
12 Jun 2025 //
GLOBENEWSWIRE
Biogen and City Therapeutics Partner on RNAi-based Therapies
27 May 2025 //
GLOBENEWSWIRE
EU authorizes Eisai-Biogen`s drug for early Alzheimer`s treatment
16 Apr 2025 //
REUTERS
Biogen’s BIIB080 Therapy Gets FDA Fast Track for Alzheimer
02 Apr 2025 //
GLOBENEWSWIRE
Organon Acquires Tofidence, a Biosimilar to Actemra in US
01 Apr 2025 //
BUSINESSWIRE
Biogen blueprints headquarters move to new digs in Cambridge
25 Mar 2025 //
FIERCE PHARMA
Biogen`s Biologic Tysabri Receives Suppl Approval in US
18 Mar 2025 //
FDA
Biogen`s Skyclarys Receives Approval in Canada
13 Mar 2025 //
HEALTH CANADA
Biogen starts Phase 3 study of Felzartamab for late AMR in kidney
11 Mar 2025 //
GLOBENEWSWIRE
NICE again rejects Alzheimer`s drugs from Lilly and Biogen/Eisai
07 Mar 2025 //
FIERCE PHARMA
EU Reaffirms Positive Opinion for Eisai-Biogen Alzheimer’s Drug
01 Mar 2025 //
REUTERS
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
19 Feb 2025 //
BIOSPACE
Biogen taps Royalty for $250M to fund phase 3 lupus
13 Feb 2025 //
REUTERS
Biogen axes asset from $7.3B buyout, plus Alzehimer’s
13 Feb 2025 //
FIERCE BIOTECH
Genentech’s Gazyva Shows Superiority in Active Lupus Nephritis
07 Feb 2025 //
BUSINESSWIRE
Sage rejects Biogen`s $469 million takeover offer
28 Jan 2025 //
BIOSPACE
FDA OKs monthly maintenance dosing for Eisai/Biogen`s AD drug
27 Jan 2025 //
PRESS RELEASE
Biogen Trims Research Workforce, SMA Drug Accepted for Review
24 Jan 2025 //
BIOSPACE
FDA & EMA Accept Higher Dose Nusinersen Applications In SMA
23 Jan 2025 //
GLOBENEWSWIRE
Biogen CEO sees no burning need for more acquisitions
15 Jan 2025 //
REUTERS
FDA Accepts LEQEMBI BLA for Subcutaneous Maintenance Dosing for AD
13 Jan 2025 //
PR NEWSWIRE
Biogen proposes to buy stake in Sage in $442 million deal
11 Jan 2025 //
REUTERS
Chung-Ang Researchers Reveal Transfer RNA`s Role In Cancer Progress
12 Dec 2024 //
PR NEWSWIRE
n-Lorem Hosts Nano-Rare Colloquium With 750+ Attendees
12 Dec 2024 //
BUSINESSWIRE
Private Medicare Plans Must Cover Biogen`s ALS Drug
12 Dec 2024 //
REUTERS
Leqembi (Lecanemab) Launched in South Korea for Alzheimer`s Disease
27 Nov 2024 //
PR NEWSWIRE
Dapirolizumab Pegol Ph 3 Data Shows Lupus Disease Activity Reduction
19 Nov 2024 //
GLOBENEWSWIRE
EU backs Eisai-Biogen Alzheimer`s drug after initial rejection
16 Nov 2024 //
REUTERS
EU regulators endorse meds from BMS, J&J, Eisai and more
15 Nov 2024 //
FIERCE PHARMA
UCB & Biogen’s dapirolizumab pegol paves path for lupus treatment
13 Nov 2024 //
EXPRESSPHARMA
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
13 Nov 2024 //
BIOSPACE
Biogen buys in to molecular glues with deal worth up to $1.45B
30 Oct 2024 //
FIERCE BIOTECH
Biogen raises profit guidance as Leqembi`s launch trudges on
30 Oct 2024 //
FIERCE PHARMA
Eisai Presents Lecanemab Long-Term Data at CTAD Conference
30 Oct 2024 //
GLOBENEWSWIRE
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
29 Oct 2024 //
GLOBENEWSWIRE
Biogen and Neomorph Collaborate on Molecular Glue Degraders
29 Oct 2024 //
GLOBENEWSWIRE
CFO Michael McDonnell to Retire in February 2025
28 Oct 2024 //
#N/A
Biogen Reports Positive IGNAZ Phase 2 Results in IgA Nephropathy
26 Oct 2024 //
GLOBENEWSWIRE
Biogen To Present Data At CTAD 2024 Annual Conference
24 Oct 2024 //
GLOBENEWSWIRE
Biogen Announces New Data Presentations At ASN Kidney Week
22 Oct 2024 //
GLOBENEWSWIRE
Suboptimal Leqembi vials could create millions in waste
15 Oct 2024 //
FIERCE PHARMA
Suboptimal Leqembi vials could create millions in waste: study
14 Oct 2024 //
FIERCE PHARMA
